絞り込み

16548

広告

Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US.

著者 McGrath LJ , Overman RA , Reams D , Cetin K , Liede A , Narod SA , Brookhart MA , Hernandez RK
Clin Epidemiol.2018 ; 10():1349-1358.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (18view , 0users)

Full Text Sources

Bone-modifying agents (BMAs) are recommended for women with bone metastasis from breast cancer to prevent skeletal-related events. We examined the usage patterns and identified the factors associated with the use of BMAs (denosumab and intravenous bisphosphonates) among women in the US.
PMID: 30288124 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード